A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100)
Public ClinicalTrials.gov record NCT02603432. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A PHASE 3, MULTICENTER, MULTINATIONAL, RANDOMIZED, OPEN-LABEL, PARALLEL-ARM STUDY OF AVELUMAB (MSB0010718C) PLUS BEST SUPPORTIVE CARE VERSUS BEST SUPPORTIVE CARE ALONE AS A MAINTENANCE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER WHOSE DISEASE DID NOT PROGRESS AFTER COMPLETION OF FIRST-LINE PLATINUM-CONTAINING CHEMOTHERAPY
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The main purpose of this study is to compare maintenance treatment with avelumab plus best supportive care (BSC) with BSC alone, to determine if avelumab has an effect on survival in patients with locally advanced or metastatic urothelial cancer that did not worsen during or following completion of first-line chemotherapy.
Study identification
- NCT ID
- NCT02603432
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 700 participants
Conditions and interventions
Conditions
Interventions
- Avelumab Biological
- Best Supportive Care Other
- Following the planned interim analysis for this study: Avelumab Biological
Biological · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 25, 2016 (Actual)
- Primary completion
- Oct 21, 2019 (Actual)
- Completion
- Mar 28, 2023 (Actual)
- Last update posted
- Mar 27, 2024
2016 – 2023
United States locations
- U.S. sites
- 19
- U.S. states
- 7
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Anschutz Cancer Center Pavilion Pharmacy | Aurora | Colorado | 80045 | — |
| University of Colorado Cancer Center | Aurora | Colorado | 80045 | — |
| University of Colorado Denver, CTO (CTRC) | Aurora | Colorado | 80045 | — |
| University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP) | Aurora | Colorado | 80045 | — |
| University of Colorado Hospital - Anschutz Outpatient Pavilion (AOP) | Aurora | Colorado | 80045 | — |
| Smilow Cancer Hospital at Yale New Haven | New Haven | Connecticut | 06510 | — |
| Smilow Cancer Hospital at Yale-New Haven | New Haven | Connecticut | 06510 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| University of Minnesota Medical Center | Minneapolis | Minnesota | 55455 | — |
| University of Minnesota | Minneapolis | Minnesota | 55455 | — |
| Cleveland Clinic Taussing Cancer Center | Cleveland | Ohio | 44106 | — |
| Cleveland Clinic Taussing Cancer Center | Cleveland | Ohio | 44160 | — |
| Cleveland Clinic Foundation | Cleveland | Ohio | 44195 | — |
| Cleveland Clinic Taussing Cancer Center | Cleveland | Ohio | 44195 | — |
| Inova Schar Cancer Institute Infusion Pharmacy | Fairfax | Virginia | 22031 | — |
| Inova Schar Cancer Institute | Fairfax | Virginia | 22031 | — |
| Seattle Cancer Care Alliance | Seattle | Washington | 98109-1023 | — |
| Seattle Cancer Care Alliance | Seattle | Washington | 98109 | — |
| University of Washington Medical Center | Seattle | Washington | 98195 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 363 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02603432, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 27, 2024 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02603432 live on ClinicalTrials.gov.